[Docetaxel and novel strategies in the treatment of NSCLC].
Longo
Flavia
F
Servizio di Oncologia Medica, Policlinico Umberto I, Roma.
Mansueto
Giovanni
G
D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D000068579:Celecoxib; D002986:Clinical Trials as Topic; D000077143:Docetaxel; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D010597:Pharmacogenetics; D011720:Pyrazoles / Q000008:administration & dosage; D013449:Sulfonamides / Q000008:administration & dosage; D043823:Taxoids / Q000627:therapeutic use*
D000972:Antineoplastic Agents, Phytogenic; D007155:Immunologic Factors; D011720:Pyrazoles; D013449:Sulfonamides; D043823:Taxoids; D000077143:Docetaxel; D000068579:Celecoxib